This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
- Investigator
- Tung T Wynn
- Ages
- 12 Years - 75 Years
- Sexes
- All
Clinical trials
-
VIVID-6 -
WP45338 This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab prophylaxis in participants aged 1 month and above, who have been diagnosed with Type 3 von…
- Investigator
- Tung T Wynn
- Ages
- 1 Month - N/A
- Sexes
- All